New hope for a rare Heart-Lung disease: can a novel drug reverse damage?
NCT ID NCT07357974
Summary
This study is testing if a new drug called sotatercept can reduce harmful tissue changes in the lungs and heart of people with pulmonary arterial hypertension (PAH), a rare and serious disease. Researchers will use advanced imaging scans to see if the drug helps control the disease by targeting a different pathway than current treatments. The study will enroll 15 adults with PAH who are already on standard therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chu Brest
Brest, Finistere, 29200, France
Contact
Conditions
Explore the condition pages connected to this study.